Kestra Medical Technologies (NasdaqGS:KMTS) Q3 2026 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsBrian Webster - President and CEODavid Roman - Managing DirectorNathan Treybeck - VP of Equity ResearchNeil Bhalodkar - VP of Investor RelationsRick Wise - Managing DirectorTravis Steed - Managing Director, Equity Research, and Medical TechnologyVaseem Mahboob - CFOConference Call ParticipantsMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMatthew O'Brien - Sen ...

Trevi Therapeutics (NasdaqGM:TRVI) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsAlexa Deemer - VP of Biotechnology Equity ResearchBrandon Folkes - Managing Director of Biopharma Biotechnology Equity ResearchDavid Hastings - CFODebanjana Chatterjee - VP of Healthcare ResearchFarrell Simon - Chief Commercial OfficerJames Cassella - Chief Development OfficerJayed Momin - Biopharma Equity Research AssociateJennifer Good - President and CEORyan Deschner - Equity Research AssociateConferen ...

Energy Vault (NYSE:NRGV) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsMichael Beer - CFONoel Parks - Managing Director of Energy ResearchRobert Piconi - Chairman and CEOSid Rajeev - Head of ResearchOperatorPlease note this conference is being recorded. I will now turn the conference over to your host, Michael Beer, Chief Financial Officer. Please go ahead, sir.Michael BeerThank you. Hello, and welcome to Energy Vault's fourth quarter and full year 2025 financial results conference ca ...

Bob's Discount Furniture (NYSE:BOBS) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Speaker8Thank you, and good afternoon, everyone. Welcome to Bob's Discount Furniture 2025 fourth quarter and full year earnings conference call. At this time, we kindly request that all participants remain in listen-only mode. A question and answer session will follow the formal prepared remarks. As a reminder, this conference call is being webcast live and recorded for replay. On the call today are Bill Barton, President ...

Financial Data and Key Metrics Changes - Q4 revenue reached $153.3 million, a significant increase from $33.5 million in the prior year quarter, reflecting strong project execution in Australia and the US [35] - Full year revenue was $203.7 million, representing over 340% growth year-over-year, driven by energy storage solutions ramp-up [35] - GAAP gross profit for Q4 was $31.6 million, compared to $2.6 million in the prior year quarter, resulting in a gross margin of 20.6% versus 7.8% [36] - Full year GAAP gross profit reached $48 million, improving nearly eight-fold versus the prior year, with a gross margin of 23.6%, up 10 percentage points from 13.4% [36] - Adjusted EBITDA turned positive at $9.8 million in Q4, compared to a loss of $13.4 million in the prior year quarter [36] - Total cash as of December 31, 2025, was $103.4 million, up more than three-fold versus the prior year [37] Business Line Data and Key Metrics Changes - The company reported a contract backlog of $1.3 billion, representing 3x growth versus the prior year and 42% sequential growth [39] - Contracted megawatts increased to 540 MW, which includes projects in operation and construction [8][16] - The Asset Vault platform is expected to generate $10 million in annualized adjusted EBITDA from the first two operational assets [43] Market Data and Key Metrics Changes - The company is actively progressing opportunities valued at more than $3 billion associated with 1.8 gigawatts of capacity [42] - The Australian development partner was awarded a 14-year long-term energy service agreement for the Ebor battery project [39] Company Strategy and Development Direction - The company is transitioning to an Asset Vault model, focusing on owning and operating energy storage projects rather than just delivering technology [15][19] - The strategy aims to create predictable, recurring, and high-margin infrastructure cash flows while unlocking synergies with the EPC integration business [43] - The company is targeting to scale to over 3 gigawatts by 2030, with a projected EBITDA of $1.5 billion+ [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in liquidity and the ability to execute the growth strategy, highlighting the importance of cash for project financing [11][14] - The company faced challenges in the first half of 2025 due to tariffs and market uncertainty but managed to achieve its original revenue guidance [10][21] - The outlook for 2026 estimates revenue in the range of $225-$300 million, reflecting growth from third-party projects and contributions from the Asset Vault [44] Other Important Information - The company completed a $300 million preferred equity agreement to support the Asset Vault platform [38] - The company is focusing on sustainability, finishing in the top 2% in S&P Global's corporate sustainability assessments [25] Q&A Session Summary Question: Can you discuss the evolution of the EMS platform? - Management highlighted significant investments in software to optimize operations and asset management, including predictive analytics for safety and efficiency [50][51] Question: What are the market trends for fuel cells in data centers? - The company is exploring various technologies to optimize data center operations, including hybrid systems that combine renewable and storage assets [56][57] Question: Can you provide details on project financing for Sosa and Stony Creek? - The Sosa project is expected to cost $125 million-$150 million, while Stony Creek is quoted at AUD 350 million, with expected project leverage exceeding 50% [70][71] Question: How much of the 2025 revenue comes from third-party deployments versus Asset Vault? - The majority of revenue in 2026 is expected to come from third-party projects, with Asset Vault contributing upwards of $10 million in recurring EBITDA [72][76] Question: Does the contract backlog include the latest project signed after December? - Yes, the backlog includes the fifth project, with additional upside associated with the fourth project [78]

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, compared to $31.4 million in 2024, marking an increase of approximately 18% [10] - The gross margin for the full year 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities for 2025 were $23.9 million, an increase of $15 million from 2024, primarily due to a higher net loss and pay down of accounts payable [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery navigation revenue grew to $14.8 million in 2025, including $1.2 million from the IRRAS product line, attributed to an increased installed base and the full market release of new systems [11] - Capital equipment and software revenue was $3.1 million for 2025, showing a slight decrease compared to the previous year [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - ClearPoint is participating in more than 25 active clinical trials and has over 60 active biopharma partners, with more than 10 partner programs accepted for FDA expedited review [5][24] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate a $1 billion market and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in various segments, including pre-commercial biologics and drug delivery, neurosurgery navigation, laser therapy, and neurocritical management [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strong position and momentum going into 2026, highlighting the successful integration of the IRRAS acquisition and the potential for significant revenue growth [21] - The management noted that the FDA's recent communications regarding rare diseases have influenced revenue guidance, leading to a more cautious approach in forecasting [41] Other Important Information - The company has invested over $100 million in the past five years to build a strong foundation, including a robust pipeline of development programs and an expanded manufacturing footprint [5] - ClearPoint's unique biologics and drug delivery ecosystem is expected to play a crucial role in the future of neurological treatments, with a focus on supporting biopharma partners [4][26] Q&A Session Summary Question: Clarification on 2026 guidance and organic growth - Management explained that the guidance was tightened due to FDA communications on rare diseases and the integration of IRRAS, with expectations for balanced organic and inorganic growth [38][46] Question: Pathway to $200 million revenue - Management indicated that they expect to grow at a rate of 15%-20% as they capture market share across their segments, with potential for significant revenue bumps from large GLP studies [48][50] Question: Updates on expedited review partners - Management confirmed that there are over 10 partners in expedited review pathways, with indications including Parkinson's disease and drug-resistant epilepsy, providing higher confidence in potential revenue [60][61] Question: Timeline for expansion in neuro-oncology - Management discussed the strength of their commercial team and the importance of upcoming clinical data to support expansion into neuro-oncology, indicating a serious commitment to this market [62]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash and cash equivalents were $9.9 million, with a subsequent capital raise of $22.3 million in January 2026, extending the company's runway [22][23] - Operating expenses were reduced by approximately $10 million across R&D and SG&A for the full year of 2025, with R&D expenses at $9.4 million and SG&A at $5.1 million for Q4 2025, down from $12.4 million and $6.8 million respectively in the prior year [23][24] - The net loss for Q4 2025 was $31.9 million, compared to $25.8 million in the same period last year [24] Business Line Data and Key Metrics Changes - The rice program is projected to generate $200 million in potential annual royalty opportunities through herbicide-tolerant traits, with initial market entry in Latin America expected in 2027 [9][10] - The sustainable ingredients program has completed pre-commercial pilot runs for two biofragrance products, leading to the first payment in Q4 2025, with potential annual royalties estimated between $20 million and $40 million [14][15] Market Data and Key Metrics Changes - The EU's political agreement on New Genomic Techniques legislation opens up approximately 100 million acres of greenfield opportunity, significantly impacting the gene editing market [16] - The company is targeting 5-7 million acres in the Americas for its rice traits, with potential expansion into the Indian market, which encompasses around 120 million acres [44] Company Strategy and Development Direction - The company is transitioning to a commercially driven model, focusing on gene editing as a core technology for agricultural innovation [5][6] - Cibus aims to serve as a gene editing engine for plant breeding capabilities, moving beyond traditional trait licensing to establish ongoing genomic editing relationships with seed companies [6][8] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a year focused on execution and momentum, with plans to expand customer relationships and advance commercialization agreements [27] - The regulatory landscape is evolving positively, with significant developments in Europe and the Americas that are expected to accelerate commercial conversations globally [16][27] Other Important Information - The company has consolidated operations from its Oberlin facility into its San Diego headquarters, which is part of a broader effort to streamline operations and reduce cash usage [24][25] - The advancements in gene editing technology have led to improved efficiency and scalability, enabling the company to respond to market demands more effectively [18][46] Q&A Session Summary Question: Impact of EU NGT framework on CapEx and canola program - Management highlighted the EU regulatory progress as a watershed moment, opening up significant opportunities for crops like winter oilseed rape, which is a major crop in Europe [32][33] Question: Next steps for rice commercialization in Latin America - The company outlined the process of editing elite genetics and the partnership with Interoc for commercialization in Ecuador and Colombia, with a focus on chemical registration and trait work [36][38] Question: Trend line for acres touched by technology - Management indicated a target of 5-7 million acres in the Americas, with potential for additional revenue from the Indian market in the future [44] Question: Scale of gene editing services - The company emphasized its efficient production system and automation, which allows for rapid scaling of gene editing services without significant increases in R&D expenses [46][49] Question: Royalty rates for gene edits as a service - Management noted that the speed and scalability of their gene editing process allow for favorable negotiations on trait royalties, as customers can see value added quickly [51][52] Question: Scale of fragrance projects - The company is currently focused on a few fragrances but sees potential to scale quickly, targeting around 17 fragrances for future development [53]

Financial Performance - In Q3 2026, revenue reached $24.6 million, reflecting a 63% increase year-over-year [8][19] - Gross margin improved to 52.6%, up 9 percentage points year-over-year and 200 basis points sequentially, marking the ninth consecutive quarter of gross margin expansion [8][19] - The company aims for gross margins of 70% or higher in the coming years [9][20] Business Line Performance - The company accepted over 5,400 prescriptions for the ASSURE System, contributing to a 58% year-over-year increase in prescriptions [8][19] - The conversion rate improved to approximately 46%, up from an adjusted 43% in the prior year [20] Market Dynamics - The wearable cardioverter defibrillator (WCD) market is estimated to have grown in the low to mid-teens percentage range in 2025, with expectations for continued expansion into a multi-billion-dollar market [10][11] - The company has seen increased market share and is actively expanding its sales organization to penetrate existing accounts and attract new prescribers [14][17] Strategic Direction - The company is focused on enhancing its product offerings, including a new ASSURE algorithm update approved by the FDA, aimed at reducing false alarms and inappropriate shocks [12][68] - A strategic collaboration with Biobeat Technologies was announced to integrate advanced blood pressure monitoring into the ASSURE WCD product line [12][13] Management Commentary - Management expressed confidence in the company's growth trajectory, citing strong revenue growth and operational leverage as key drivers for long-term value [9][17] - The management team highlighted the importance of clinical data from the ACE-PAS study in driving clinician engagement and market expansion [11][49] Other Important Information - The company has recently become an approved provider for Florida's managed Medicaid, which is expected to enhance market access and growth in that state [16][60] - The monthly Medicare reimbursement rate for WCDs increased by 2% to $3,589, positively impacting revenue cycle management [16] Q&A Session Summary Question: Thoughts on early 2027 model and consensus - Management is confident in delivering top-tier med tech growth in 2027 but will provide detailed guidance at the next earnings call [29] Question: Acceleration in WCD market growth - The acceleration is attributed to an expanded commercial team and clinical studies highlighting patient risks, which are driving market growth [30][32] Question: Prescription growth sources - Approximately 70%-75% of prescription growth is from market share shift, with 25% from new prescribers [37] Question: Competitive environment and pricing - There are no significant pricing headwinds, and the competitive landscape remains stable with entrenched competitors focusing on service levels [41][46] Question: Florida market access impact - Gaining Medicaid provider status is expected to enhance market share and gross margins in Florida, although growth will be gradual [60][61] Question: Future territory expansion plans - The company is evaluating the pace of territory expansion and is open to accelerating growth based on market conditions [52] Question: Cash burn and CapEx outlook - Cash burn is expected to remain in the mid-$20 million range, with ongoing investments in CapEx to support growth [86]

Financial Data and Key Metrics Changes - The company ended 2025 with approximately $188 million in cash equivalents and marketable securities, providing a runway into 2028 to fund key clinical trials [15][14] - The cash runway is expected to support top-line data in pivotal phase 3 clinical trials for IPF-related chronic cough and phase 2B trials for RCC and non-IPF ILD [15] Business Line Data and Key Metrics Changes - The company is preparing to initiate two pivotal phase 3 clinical trials for Haduvio in IPF-related chronic cough, with the first trial expected to start in Q2 2026 [6][4] - The second phase 3 trial is anticipated to begin in the second half of 2026, focusing on a 12-week primary efficacy endpoint [6][7] Market Data and Key Metrics Changes - In the US, there are approximately 150,000 IPF patients, with two-thirds experiencing uncontrolled chronic cough, indicating a significant unmet medical need [8] - The market opportunity for non-IPF ILD patients is estimated to be around 228,000, with 50%-60% suffering from uncontrolled cough, effectively doubling the market potential [10] Company Strategy and Development Direction - The company aims to become a leader in chronic cough treatment, focusing on developing therapies for patients with high unmet needs [12] - The strategy includes conducting adaptive phase 2B trials for non-IPF ILD and refractory chronic cough, with plans to file supplemental NDAs for these indications [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clarity of the path forward for registration trials following positive FDA interactions [5][4] - The company is optimistic about the enrollment demand for the IPF chronic cough pivotal study, citing increased awareness among physicians and patient advocacy groups [78][77] Other Important Information - The company plans to hold an investor and analyst day on May 7, 2026, to discuss clinical and commercial strategies in detail [12] - The company will also participate in the American Thoracic Society meeting, sharing new data from various trials [12] Q&A Session Summary Question: Can you elaborate on the remaining phase 1 studies discussed with the FDA? - The studies are label-informative, focusing on drug-drug interactions and metabolism, which are not rate-limiting and can be conducted in parallel with phase 3 trials [17][19] Question: What design features are being aligned with the FDA for the non-IPF ILD trial? - The company plans to propose an adaptive phase 2B trial design, leveraging insights from the IPF end-of-phase 2 meeting [20][22] Question: Will the label dose in RCC be the same as in IPF? - The company is exploring the dosing strategy and may require additional IP if the dosing differs significantly [58] Question: What are the expectations for recruitment pace in the phase 3 IPF cough trial? - The company anticipates a one-year enrollment period for the phase 3 trial, focusing on 80 to 100 sites primarily in the US [102] Question: Will there be any pre-specified analyses for dyspnea and exacerbations in the phase 3 trial? - The company will track various metrics related to cough, breathlessness, and other patient concerns, but the primary focus remains on cough [116][115]

Summary of Casella Waste Systems Conference Call Company Overview - **Company**: Casella Waste Systems (NasdaqGS:CWST) - **Date of Conference**: March 17, 2026 - **Speakers**: Ned Coletta (CEO), Brad Helgeson (CFO) Key Points Company Strategy and Leadership Changes - **CEO Priorities**: - Focus on workforce safety and engagement, modernizing core values, and ensuring purposeful work alignment across departments [7][8][9] - **Leadership Changes**: - Departure of COO Sean M. Steves and hiring of Chris Rains as new Chief Revenue Officer, emphasizing a shift towards digital customer engagement [10][11] Revenue Mix and Market Position - **Revenue Composition**: - Approximately 70% of revenue from open markets, allowing for flexible pricing, and 30% from long-term contracts with large industrial and municipal customers [13] - **Pricing Strategy**: - Targeting a minimum price-cost spread of 50 basis points to maintain margins, with a current guidance of about 5% pricing in solid waste [19][20] Volume and Growth Expectations - **Volume Outlook**: - Anticipating flat to down volume growth, with a long-term target of marginally positive growth, prioritizing revenue quality over volume [21][22] - **Landfill Capacity**: - Casella holds a leading position in the Northeast with over 20 years of average capacity across its landfill portfolio, facing challenges from regulatory pressures and landfill closures [25][26] M&A Strategy - **Acquisition Activity**: - Acquired $330 million in revenues in 2023, with expectations to acquire $150-$180 million in 2024. The addressable market for acquisitions is in the billions [35][36] - **M&A Framework**: - Focus on achieving a low teens IRR on acquisitions, with a strategy to leverage tax structuring for enhanced cash flows [38][39] Cost Management and Efficiency - **SG&A Improvements**: - Current SG&A at over 12% of revenue, with a target to reduce it to around 10% through technology implementation and operational efficiencies [44][45] - **Cost Savings Initiatives**: - Targeting $15 million in operating cost savings over the next few years, with $5 million expected in the current year from the Mid-Atlantic region [47][48] Market Conditions and External Factors - **Impact of Weather**: - Noted that the Northeast experienced one of the coldest winters in 25 years, affecting economic activity and productivity, but also benefiting ski area services [57][58] Resource Solutions Business - **Business Model**: - The Resource Solutions segment is insulated from commodity price volatility through floating fees and risk-sharing with third-party customers, ensuring stable returns [50][51][52] Additional Insights - **Future Growth**: - Casella is focused on organic growth and strategic acquisitions within existing markets, avoiding significant geographic expansion for the time being [49] - **Financial Position**: - The company has approximately $800 million in liquidity and is positioned to pursue acquisition opportunities without current buybacks [56] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Casella Waste Systems' operational focus, market positioning, and future growth strategies.